We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(ESMO) Dec 15, 2017 - ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care in its leading scientific journal, Annals of Oncology (1) today.
(Moffitt Cancer Center) Dec 12, 2017 - Men infected with HPV16, the type responsible for most HPV-related cancers, are 20 times more likely to be reinfected with the same type of HPV after one year.
(Bloomberg) Dec 14, 2017 - Congress has found little to agree on when it comes to health care, but lawmakers from both parties appear to be warming up to ideas for reining in drug prices.
(Journal of Clinical Pathways) Dec 15, 2017 - A recently approved second-line therapy is reasonably effective in the treatment of advanced non-small cell lung cancer (NSCLC), according to a recent real-world study.
(Kaiser Health News) Dec 15, 2017 - Genetic testing firms declare bankruptcy and wipe out debt to the federal government.
(CUMC) Dec 14, 2017 - Cancer cells arise when DNA is mutated, and these cells should be recognized as “foreign” by the immune system. However, cancer cells have found ways to evade detection by the immune system.
(Politico) Dec 15, 2017 - It’s a mess that can happen only in Washington.
(Rutgers/CINJ) Dec 14, 2017 - Predicting how patients will respond to anti-cancer therapies can be vital in informing clinical decisions and improving treatment outcome.
(WebMD/HealthDay News) Dec 15, 2017 - A new drug that targets a genetic flaw common to most cancer cells is showing potency against many tumor types.
(Merck) Dec 15, 2017 - Merck, known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-061 trial investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, did not meet its primary endpoint of overall survival (OS) (HR, 0.82 [95% CI, 0.66-1.03]; p=0.042 [one-sided]) in patients whose tumors expressed PD-L1 [Combined Positive Score (CPS) ≥ 1].